当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Ludy Monga
Background: Radiotherapy is typically regarded as an absolute exclusion criterion for prostate cancer radiotherapy treatment in patients with active inflammatory bowel disease. There are no reports on the application of a biodegradable rectal balloon implantation for prostate cancer radiation in patients with active IBD. Presentation of the case: We describe a guy who had high-risk prostate cancer and an active IBD with pancolitis as a concomitant condition. Neo-adjuvant hormonal therapy and high-dose external beam radiation to the prostate and seminal vesicles were used in his treatment. In order to move the rectum outside of the high-dose region prior to radiotherapy treatment, a biodegradable RBI was inserted between the prostate and the anterior rectal wall. The prostate of this patient, who was at high risk for rectal toxicity, was effectively exposed to radiation using only a grade A biodegradable sub acromial spacer of the In Space type was the foundation of a minimally invasive procedure that was recently released on the market. As the name implies, the treatment entails inserting this saline-filled device as a spacer between the acromion and the humeral head in the sub acromial space.